Towards Development of Antibodies Targeting Myeloid and Regulatory T Cells in Bladder Tumours
Checkpoint inhibition is an attractive option for treating bladder cancer, the tenth most common type of cancer in the world. With currently approved drugs restricted to targeting the PD1/PD-L1 axis with limited response rates, finding alternative targets for manipulation of immune cells could improve the survival of bladder cancer patients. Recently, cell markers selectively expressed by immunosu
